Synergy Pharmaceuticals Inc (SGYP) 2.98 $SGYP
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Synergy's Constipated Share Price Is Headed For A Cure
Scrying Biotech - at Seeking Alpha - Wed Feb 04, 5:30AM CST
SGYP: 2.98 (unch), IRWD: 15.15 (-0.85)
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences
Business Wire - Tue Feb 03, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.
SGYP: 2.98 (unch)
Synergy Pharma completes patient enrollment plecanatide Phase 3
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:38AM CST
SGYP: 2.98 (unch)
Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Thu Jan 29, 5:01AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment in the second of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). Synergy announced that it had completed patient enrollment in the first phase 3 CIC trial on January 8, 2015.
SGYP: 2.98 (unch)
3 Stocks That Should Move Significantly Higher Soon
StockMatusow - Seeking Alpha - Wed Jan 28, 12:54PM CST
By Scott Matusow Fairway Group Holdings Corp. (NASDAQ: FWM ): Fairway Group Holdings Corp. operates as a holding company with interests in food retail stores. The company focuses on perishable product categories, which include produce, natural...
WFM: 56.15 (-0.15), SGYP: 2.98 (unch), INVE: 11.86 (+0.30), FWM: 5.55 (+0.08), AAPL: 127.08 (+0.62)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 2.98 (unch), SHPG: 239.82 (+6.11), AZN: 69.96 (+0.20), SCMP: 15.32 (+0.04), TEVA: 56.77 (-0.58)
ContraVir to Present at Noble Financial Conference
PR Newswire - Thu Jan 15, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference, to be held January 18-21, 2015, in Sandpiper Bay, FL.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
PR Newswire - Tue Jan 13, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of John Sullivan-Bolyai, M.D., MPH, as the Company's Chief Medical Officer.
SGYP: 2.98 (unch)
Patient enrollment complete in Phase 3 plecanatide trial
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 9:38AM CST
SGYP: 2.98 (unch)
Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Thu Jan 08, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment in the first of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC).
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals adds Renu Gupta, M.D., to Scientific Advisory Board
PR Newswire - Thu Jan 08, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the addition of Renu Gupta, M.D., to the Company's Scientific Advisory Board (SAB), formed in December 2014, to support the development of its targeted antiviral therapies including their lead antiviral product candidate, FV-100, the primary value driver for ContraVir.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
PR Newswire - Wed Jan 07, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. The meeting will take place in the first quarter of 2015 and will focus on evaluating both completed and planned FV-100 clinical studies, including the proposed upcoming Phase 3 trial of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
SGYP: 2.98 (unch)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 2.98 (unch), CMRX: 40.16 (+0.08)
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
Business Wire - Thu Dec 18, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, for the treatment of irritable bowel syndrome with constipation (IBS-C). Synergy is also evaluating 3.0 and 6.0 mg doses of plecanatide in two ongoing pivotal phase 3 trials for chronic idiopathic constipation (CIC), scheduled to read out top-line results in second quarter and third quarter 2015.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 2.98 (unch)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
Seeking Alpha's Biotech Weekly: Questioning Gilead, MannKind To Market, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Feb 06, 3:00PM CST
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
SGYP: 2.98 (unch), BLUE: 90.70 (+0.93), ZIOP: 9.64 (-0.35), MYGN: 34.03 (+0.40), PSTI: 2.91 (+0.01), PFE: 34.64 (-0.23), XON: 39.30 (+1.05), TKMR: 21.45 (-0.22), ASPX: 65.76 (+2.76), MNKD: 7.00 (+0.02), HSP: 87.35 (unch), ZTS: 45.46 (-0.33), ANTM: 141.05 (-0.95), WMGI: 25.68 (+0.17), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), THOR: 40.01 (+0.54), TEVA: 56.77 (-0.58), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ARNA: 4.55 (+0.02)
Synergy's Constipated Share Price Is Headed For A Cure
Scrying Biotech - at Seeking Alpha - Wed Feb 04, 5:30AM CST
SGYP: 2.98 (unch), IRWD: 15.15 (-0.85)
Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences
Business Wire - Tue Feb 03, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will present a corporate update at two February investment conferences being held at the Waldorf Astoria in New York, N.Y.
SGYP: 2.98 (unch)
Synergy Pharma completes patient enrollment plecanatide Phase 3
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 11:38AM CST
SGYP: 2.98 (unch)
Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Thu Jan 29, 5:01AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment in the second of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). Synergy announced that it had completed patient enrollment in the first phase 3 CIC trial on January 8, 2015.
SGYP: 2.98 (unch)
3 Stocks That Should Move Significantly Higher Soon
StockMatusow - Seeking Alpha - Wed Jan 28, 12:54PM CST
By Scott Matusow Fairway Group Holdings Corp. (NASDAQ: FWM ): Fairway Group Holdings Corp. operates as a holding company with interests in food retail stores. The company focuses on perishable product categories, which include produce, natural...
WFM: 56.15 (-0.15), SGYP: 2.98 (unch), INVE: 11.86 (+0.30), FWM: 5.55 (+0.08), AAPL: 127.08 (+0.62)
Constipation Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Sun Jan 25, 10:30AM CST
The report "Constipation - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Constipation. Constipation is a disorder in which a person has severe problems defecating. Constipation occurs primarily because of the lack of the bowel movement in the body. The Lack of bowel movement in the body results in hardening of stools, swollen abdomen or abdominal pain. The reasons for constipation to occur in a body are inadequate water intake, less proportion of fiber in diet, irregularities in the pattern of diet. Not maintaining proper health and inadequacy in exercise can also lead to the abnormality during defecation & would mostly end with painful symptoms. Complete Report is Available @ http://www.rnrmarketresearch.com/constipation...eport.html .
SGYP: 2.98 (unch), SHPG: 239.82 (+6.11), AZN: 69.96 (+0.20), SCMP: 15.32 (+0.04), TEVA: 56.77 (-0.58)
ContraVir to Present at Noble Financial Conference
PR Newswire - Thu Jan 15, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference, to be held January 18-21, 2015, in Sandpiper Bay, FL.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals Appoints John Sullivan-Bolyai, M.D., MPH, as Chief Medical Officer
PR Newswire - Tue Jan 13, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the appointment of John Sullivan-Bolyai, M.D., MPH, as the Company's Chief Medical Officer.
SGYP: 2.98 (unch)
Patient enrollment complete in Phase 3 plecanatide trial
Seeking Alpha - at Seeking Alpha - Thu Jan 08, 9:38AM CST
SGYP: 2.98 (unch)
Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Business Wire - Thu Jan 08, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment in the first of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC).
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals adds Renu Gupta, M.D., to Scientific Advisory Board
PR Newswire - Thu Jan 08, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the addition of Renu Gupta, M.D., to the Company's Scientific Advisory Board (SAB), formed in December 2014, to support the development of its targeted antiviral therapies including their lead antiviral product candidate, FV-100, the primary value driver for ContraVir.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100
PR Newswire - Wed Jan 07, 5:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has been granted a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss its proposal for the design of a Phase 3 trial of ContraVir's lead antiviral candidate, FV-100. The meeting will take place in the first quarter of 2015 and will focus on evaluating both completed and planned FV-100 clinical studies, including the proposed upcoming Phase 3 trial of FV-100 to prevent the debilitating shingles-associated pain known as post-herpetic neuralgia (PHN).
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals to Present at Biotech Showcase 2015
PR Newswire - Tue Jan 06, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB:CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that the Company is scheduled to present at the Biotech Showcase(TM) 2015 taking place in San Francisco, CA on January 12-14, 2015.
SGYP: 2.98 (unch)
Chimerix and ContraVir Pharmaceuticals Establish Strategic Collaboration for Antiviral Drug Candidate CMX157
PR Newswire Europe - Thu Dec 18, 5:00AM CST
-- ContraVir to develop CMX157 for multiple antiviral indications --
SGYP: 2.98 (unch), CMRX: 40.16 (+0.08)
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation
Business Wire - Thu Dec 18, 5:00AM CST
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, for the treatment of irritable bowel syndrome with constipation (IBS-C). Synergy is also evaluating 3.0 and 6.0 mg doses of plecanatide in two ongoing pivotal phase 3 trials for chronic idiopathic constipation (CIC), scheduled to read out top-line results in second quarter and third quarter 2015.
SGYP: 2.98 (unch)
ContraVir Pharmaceuticals Appoints Nathaniel Katz, M.D., Chairman of New Scientific Advisory Board
PR Newswire - Tue Dec 16, 6:00AM CST
ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today the formation of a Scientific Advisory Board (SAB) to support the development of the Company's targeted antiviral therapies. The Company also announced that Nathaniel Katz, M.D., global expert in post herpetic neuralgia (PHN) pain management and President and Chief Executive Officer of Analgesic Solutions, a research, education, and consulting firm focused exclusively on pain therapeutics, has joined ContraVir as Chairman of the newly formed SAB.
SGYP: 2.98 (unch)
